Pharmaceuticals
More
-
Already sluggish health-care inflation is projected to slow down even more in 2014 as consumers, employers and the federal government continue looking to cut medical costs, a new report said Tuesday.
-
June 17- Johnson& Johnson said it would pay up to $1 billion for Aragon Pharmaceuticals and its experimental drugs for prostate cancer, to bolster J&J's role in the field after it acquired another experimental prostate-cancer treatment four years ago that has become a leading brand.
-
NEW YORK-- Canadian drugmaker Valeant Pharmaceuticals International Inc. said Monday it will sell $1.75 billion in stock to help fund its acquisition of Bausch+ Lomb. It will pay $4.5 billion for the company and will spend another $4.2 billion to repay Bausch+ Lomb's debt.
-
A Supreme Court decision gives the FTC the go-ahead to continue suing drug makers over deals that delay generic versions from being sold.
-
WASHINGTON, June 17- The U.S. Supreme Court ruled on Monday regulators can challenge deals between brand-name drug companies and generic rivals that delay cheaper medicines from going on sale, which regulators say increase costs to consumers by billions of dollars.
-
NEW YORK-- Teva Pharmaceutical Industries Ltd. said Monday that it is buying MicroDose Therapeutx for $40 million to build its pipeline of respiratory products. Teva, based in Israel, is one of the world's largest makers of generic drugs. U.S.-traded shares of Teva added 20 cents to $39.28 in Monday afternoon trading.
-
NEW YORK, June 17- ViroPharma Inc, a drug maker specializing in rare diseases, is attracting preliminary acquisition interest from several pharmaceutical companies, according to three people familiar with the matter.
-
June 17- Johnson& Johnson said it would pay up to $1 billion for Aragon Pharmaceuticals and its experimental drugs for prostate cancer, bolstering J&J's role in the field after it acquired another experimental prostate-cancer treatment four years ago that has become a leading brand.
-
NEW YORK, June 17- ViroPharma Inc is attracting preliminary interest from several pharmaceutical companies about buying the orphan drugmaker, according to three people familiar with the matter.
-
The Supreme Court says deals between pharmaceutical companies and their generic drug competitors can sometimes be illegal.
-
WASHINGTON, June 17- The U.S. Supreme Court ruled on Monday that the Federal Trade Commission can challenge deals brand-name drug companies make with generic rivals that keep cheaper products off the market.
-
The FTC can challenge deals to keep generic drugs off the market, reports CNBC's Hampton Pearson.
-
SOUTH SAN FRANCISCO, Calif.-- Drug developer Theravance Inc. plans to split into two independent, publicly traded companies after a royalty agreement it had ironed out with Irish drugmaker Elan Corp. PLC fell through. South San Francisco, Calif.- based Theravance said Monday it will split into businesses named Royalty Management Co. and Theravance Biopharma.
-
Biotech and drug companies say the benefits of genome research are on the way, and just as importantly, advances are pushing the technology toward affordability.
-
NEW YORK-- Cempra's stock declined Friday as the pharmaceutical company priced a public stock offering at a 14 percent discount to its Thursday closing price. THE SPARK: Cempra Inc. priced the offering of approximately 7.3 million shares at $7 each. Cempra _ which went public in February 2012 _ said that the offering's gross proceeds were $50.8 million.
-
DUBLIN/ NEW YORK, June 14- Irish drug company Elan put itself up for sale on Friday, seeking to fend off a hostile bid by Royalty Pharma that shareholders will consider next week. "Elan Corporation... today announced that it is proceeding with a formal sale process in light of the expressions of interest received to date," the company said in a statement.
-
Biotech drugmaker Amgen Inc. said Thursday that the Food and Drug Administration has approved a new use for its bone drug Xgeva. The company, based in Thousand Oaks, Calif., said it now can market Xgeva for treating a rare condition, giant cell tumor of bone, when surgery isn't practical.
-
*E-cigarettes sold as less harmful alternative to tobacco. LONDON, June 13- Puffing on slim metal tubes loaded with pale yellow liquid, two London businessmen say they have between their lips a cure for what the U.N. calls "one of the biggest public health threats the world has ever faced".
-
WASHINGTON-- Shares of Biogen Idec fell Wednesday after an analyst said the company's new multiple sclerosis treatment could face pricing pressure in Europe from generic drugs. Yaron Werber lowered his rating on the Massachusetts biotech company's stock to "Neutral" from "Buy."
-
THOUSAND OAKS, Calif.-- Biotech drugmaker Amgen Inc. reported Wednesday that its experimental drug for ovarian cancer helped patients live 1.8 months longer without their disease spreading, compared with patients getting placebo. Amgen is studying its drug trebananib in combination with paclitaxel to treat recurring ovarian cancer.
Most Popular Video
The Fast Money traders share their final trades of the day.
Tuesday, 18 Jun 2013 | 5:00 PM ETAhead of the Fed meeting, the S&P 500 appears headed toward 1,687, StockMonster's Guy Adami says.
Tuesday, 18 Jun 2013 | 6:40 PM ETYou say the name of a stock, and Mad Money's Jim Cramer tells you whether to buy or sell.